scholarly journals The Plasma Levels of Dehydroepiandrosterone Sulfate Are Decreased in Patients with Chronic Heart Failure in Proportion to the Severity*

2000 ◽  
Vol 85 (5) ◽  
pp. 1834-1840 ◽  
Author(s):  
Yasushi Moriyama ◽  
Hirofumi Yasue ◽  
Michihiro Yoshimura ◽  
Yuji Mizuno ◽  
Koichi Nishiyama ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Heart Failure ◽  
Chronic Heart Failure ◽  
Plasma Level ◽  
Natriuretic Peptide ◽  
Plasma Levels ◽  
Thiobarbituric Acid ◽  
The Elderly ◽  
Dehydroepiandrosterone Sulfate ◽  
Significant Difference

Abstract Dehydroepiandrosterone sulfate (DHEAS) is the major secretory steroid of the human adrenal glands. The secretion of DHEAS decreases with aging. The incidence of heart failure also rises in the elderly population. We measured the plasma levels of DHEAS and cortisol in 49 patients with chronic heart failure (CHF) and 32 age-matched controls and assessed its relation to plasma levels of A-type natriuretic peptide and B-type natriuretic peptide, biochemical markers of heart failure. Plasma levels of DHEAS were significantly lower in patients with CHF than in controls, whereas there was no significant difference in plasma levels of cortisol between the two groups. In stepwise regression analysis, the plasma level of DHEAS was significantly and independently correlated with age (β = −0.451; P < 0.0001) and the plasma level of B-type natriuretic peptide (β = −0.338; P < 0.001), and the plasma cortisol/DHEAS ratio was significantly and independently correlated with the plasma levels of A-type natriuretic peptide (β = 0.598; P < 0.0001) and thiobarbituric acid-reactive substances (a marker of oxidative stress;β = 0.252; P < 0. 01) and age (β = 0.171; P < 0.05). These results indicate that the plasma levels of DHEAS are decreased in patients with CHF in proportion to its severity and that oxidative stress is associated with decreased levels of DHEAS in patients with CHF.

scholarly journals C-type natriuretic peptide plasma levels increase in patients with chronic heart failure as a function of clinical severity

2005 ◽  
Vol 7 (7) ◽  
pp. 1145-1148 ◽  
Author(s):  
Silvia Del Ry ◽  
Claudio Passino ◽  
Maristella Maltinti ◽  
Michele Emdin ◽  
Daniela Giannessi
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Natriuretic Peptide ◽  
Plasma Levels ◽  
Clinical Severity

A Novel Model to Predict Plasma Levels of N Terminal Pro-Brain Natriuretic Peptide in Patients with Chronic Heart Failure

2003 ◽  
Vol 104 (s48) ◽  
pp. 7P-7P
Author(s):  
SG Williams ◽  
DJ Wright ◽  
S Taylor ◽  
ZI Khan ◽  
R O'Brien ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Plasma Levels ◽  
Novel Model

Clinical implications of normal B-type natriuretic peptide levels in patients with severe chronic heart failure

2014 ◽  
Vol 8 (4) ◽  
pp. 493-497
Author(s):  
Changzheng Gao ◽  
Qi Lu ◽  
Suxia Guo ◽  
Zhenyu Yang ◽  
Kulin Li ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Natriuretic Peptide ◽  
Poor Prognosis ◽  
High Plasma ◽  
Clinical Implications ◽  
Severe Chronic Heart Failure ◽  
Significant Difference ◽  
Group A ◽  
Group B

Abstract Background: High plasma B-type natriuretic peptide (BNP) levels in patients with severe chronic heart failure (CHF) often indicate poor ventricular function and poor prognosis. However, in some such patients plasma BNP levels are normal. Objective: To investigate the clinical implications of BNP levels in patients with severe CHF. Methods: Fifty-seven patients with severe CHF were divided into group A (13 normal plasma BNP level) and 44 patients (high plasma BNP levels) group B. Diuretics, angiotensin-converting enzyme inhibitors (or angiotensin II receptor antagonist, e.g., metoprolol) and digitalis were used as conventional treatment. The clinical characteristics of all patients in two groups were analyzed and compared. Results: At the first admission, left ventricular end diastolic diameter in group B was significantly lower than group A (p < 0.05), and the plasma BNP level in group B was significantly higher than group A (p < 0.05). When metoprolol was used, 6 and 5 patients in group A and B could not tolerate the initial dose. In other cases using metoprolol at average maximum tolerance dose of metoprolol 12.5-6.25 and 24.20-11.22 mg/day in group A and B, respectively, there was a significant difference between them (p < 0.05). There were no significant differences in plasma BNP levels between two groups during stable period. The plasma BNP level in group B during acute worsening stage was significantly higher than in the remission stage (962.73-165.00 ng/L vs 876.24-167.70 ng/L, p < 0.05). However, there was no significant difference between group A (74.03-11.18 ng/L) and group B (71.38-11.68 ng/L) (p > 0.05). The mobility of group A was higher than group B (11/12 vs 6/44, p < 0.05). Logistic regression analysis showed that, the plasma BNP level was the independent risk factor for predicting cardiac death (regression coefficient, 3.817; OR, 45.488; 95% CI, 5.322ʺ388.791). Conclusion: In patients with severe CHF, normal plasma BNP level suggests depletion of BNP secretion and further deterioration of cardiac function, indicating a poor prognosis.

TRENDS AND PROGNOSIS OF THE INCIDENCE OF AGE-RELATED MACULAR DEGENERATION IN THE ELDERLY WITH CHRONIC HEART FAILURE

2021 ◽  
pp. 140-145
Author(s):  
Виктор Афанасьевич Иванов ◽  
Борис Дмитриевич Жидких ◽  
Елена Ефимовна Атлас ◽  
Юрий Юрьевич Блинков ◽  
Татьяна Игоревна Субботина
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Macular Degeneration ◽  
Prognostic Model ◽  
The Elderly ◽  
Age Related Macular Degeneration ◽  
Age Related ◽  
Medical Institutions ◽  
Time Period ◽  
Significant Difference

Возрастная макулярная дегенерация считается одной из распространенных возраст ассоциированных офтальмологических патологий, приводящих к полной или частичной потере зрения. Вероятность развития возрастной макулярной дегенерации существенно повышается при наличии сопутствующей хронической сердечной недостаточности. Однако изучение динамики заболеваемости возрастной макулярной дегенерацией при сочетании хронической сердечной недостаточности осуществляется крайне редко. Цель настоящего исследования - анализ заболеваемости возрастной макулярной дегенерацией и прогнозирование ее распространенности в Тамбовской области у пациентов с хронической сердечной недостаточностью. Исследование проводилось ретроспективным методом за 2013-2018 годы по данным официальной статистики лечебно-профилактических учреждений общего и специализированного профиля. При сборе информации использовались данные, содержащиеся в «Медицинской когорте амбулаторного больного», «Медицинской карте амбулаторного больного». Для прогнозирования заболеваемости возрастной макулярной дегенерацией использовался регрессионный анализ и программа «Statistica 10.0». В ходе исследования установлено повышение уровня заболеваемости с 13,54 случаев на 100 000 населения в 2013 году в базовом регионе до 28,42 случаев на 100 000 населения в 2018 году с достоверной разницей. Разработанная прогностическая модель у=0,7124 ln(x1)+1,4586 показывает, что в 2019-2021 годах произойдет дальнейшее увеличение заболеваемости возрастной макулярной дегенерацией. При этом наибольшую распространенность среди выделяемых форм возрастной макулярной дегенерации в Тамбовской области за исследуемый временной период имеет неэкссудативная форма, варьирующая в диапазоне от 12,41 случаев до 25,98 случаев на 100 000 населения (р<0,001). Экссудативная возрастная макулярная дегенерация варьирует от 1,42 случаев до 2,30 случаев на 100 000 жителей области. Полученные данные представляют интерес для принятия упреждающих профилактических мероприятий по стабилизации заболеваемости возрастной макулярной дегенерацией Age-related macular degeneration is considered one of the most common age-associated ophthalmological pathologies leading to complete or partial loss of vision. The probability of developing age-related macular degeneration increases significantly in the presence of concomitant chronic heart failure. However, the study of the dynamics of the incidence of age-related macular degeneration in combination with chronic heart failure is extremely rare. The purpose of this study is to analyze the incidence of age-related macular degeneration and predict its prevalence in the Tambov region in patients with chronic heart failure. The study was conducted retrospectively for 2013-2018 according to official statistics of general and specialized medical institutions. When collecting information, the data contained in the "Medical cohort of an outpatient patient", "The medical record of an outpatient patient" were used. Regression analysis and the Statistica 10.0 program were used to predict the incidence of age-related macular degeneration. The study found an increase in the incidence rate from 13.54 cases per 100,000 population in 2013 in the base region to 28.42 cases per 100,000 population in 2018 with a significant difference. The developed prognostic model y1=0.7124 ln(x1)+1.4586 shows that in 2019-2021 there will be a further increase in the incidence of age-related macular degeneration. At the same time, the greatest prevalence among the isolated forms of age-related macular degeneration in the Tambov region over the studied time period has a non-exudative form, varying in the range from 12.41 cases to 25.98 cases per 100,000 population (p<0.001). Exudative age-related macular degeneration varies from 1.42 cases to 2.30 cases per 100,000 inhabitants of the region. The data obtained are of interest for taking proactive preventive measures to stabilize the incidence of age-related macular degeneration

Radioimmunoassay for plasma C-type natriuretic peptide determination: a methodological evaluation

2005 ◽  
Vol 43 (6) ◽  
Author(s):  
Silvia Del Ry ◽  
Maristella Maltinti ◽  
Michele Emdin ◽  
Claudio Passino ◽  
Giosué Catapano ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Endothelial Dysfunction ◽  
Natriuretic Peptide ◽  
Plasma Levels ◽  
Extraction Yield ◽  
Analytical Sensitivity ◽  
Analytical Reliability ◽  
Preliminary Extraction ◽  
Clinical Conditions

AbstractC-Type natriuretic peptide (CNP) is a member of the family of natriuretic peptides with vasodilatory properties, and is produced and secreted by endothelial cells. It seems to play a central role in the paracrine vasomotor control of tone and to be important in several clinical conditions characterized by endothelial dysfunction. We evaluated the analytical performance of a commercially available radioimmunoassay for CNP after a preliminary extraction with Sep-Pak C18. Its analytical reliability was checked by determination of CNP plasma levels in healthy subjects (n=23) and in patients with different diseases, likely characterized by endothelial dysfunction, such as chronic heart failure (n=133) and cirrhosis (n=84). The extraction yield was 78±3%. Accuracy of the radiommunological determination was evaluated by dilution (45–370μL of extracted plasma) and recovery tests (>80%). Between- and within-assay variabilities were ≤10% and analytical sensitivity was 0.41±0.015pg/tube. Plasma CNP in patients with chronic heart failure and with cirrhosis was significantly raised compared to controls (p<0.0001 and p=0.001, respectively). The sensitivity, accuracy and variability levels of the method proposed for CNP assay was suitable for reliable detection of changes in CNP plasma levels in the clinical setting.

scholarly journals Relationship between B-type natriuretic peptide plasma levels and echocardiography parameters in compensated chronic heart failure patients treated with levosimendan

Critical Care ◽  
2007 ◽  
Vol 11 (Suppl 3) ◽  
pp. P48
Author(s):  
EJ de Almeida Figueiredo ◽  
A Perez ◽  
E Knobel ◽  
JMA Souza ◽  
MB Ferri ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Natriuretic Peptide ◽  
Plasma Levels ◽  
Heart Failure Patients
Sign in / Sign up

Export Citation Format

Share Document